LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

Odonate Therapeutics Inc

Closed

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Odonate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 maj 2025, 23:20 UTC

Earnings

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 maj 2025, 23:48 UTC

Market Talk

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 maj 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 maj 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 maj 2025, 23:24 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

13 maj 2025, 23:24 UTC

Market Talk
Earnings

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 maj 2025, 22:58 UTC

Earnings

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 maj 2025, 22:58 UTC

Earnings

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 maj 2025, 22:58 UTC

Earnings

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 maj 2025, 22:58 UTC

Earnings

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 maj 2025, 22:38 UTC

Earnings

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 maj 2025, 22:38 UTC

Earnings

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 maj 2025, 22:37 UTC

Earnings

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 maj 2025, 22:36 UTC

Earnings

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 maj 2025, 22:35 UTC

Earnings

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 maj 2025, 22:34 UTC

Earnings

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 maj 2025, 22:33 UTC

Earnings

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 maj 2025, 22:33 UTC

Earnings

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 maj 2025, 22:33 UTC

Earnings

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 maj 2025, 22:30 UTC

Earnings

Aristocrat Interim Dividend 44 Australian Cents/Share

13 maj 2025, 22:30 UTC

Earnings

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 maj 2025, 22:29 UTC

Earnings

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 maj 2025, 22:28 UTC

Earnings

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 maj 2025, 21:15 UTC

Earnings

Nu Holdings 1Q Rev $3.2B >NU

13 maj 2025, 21:03 UTC

Top News

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 maj 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 maj 2025, 20:32 UTC

Earnings

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 maj 2025, 20:31 UTC

Earnings

Alcon 1Q Sales $2.45B >ALC.EB

13 maj 2025, 20:30 UTC

Earnings

Alcon 1Q Rev $2.47B >ALC.EB

13 maj 2025, 20:30 UTC

Earnings

Alcon 1Q EPS 70c >ALC.EB

Peer Comparison

Price change

Odonate Therapeutics Inc Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.